November 14, 2024
National Institute on Drug Abuse (NIDA)
The purpose of this Guide Notice is to inform potential applicants regarding correction to the due date of RFA-DA-26-018 Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional) and increase of the award budget for RFA-DA-26-018 Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional) and RFA-DA-26-019 Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)
RFA-DA-26-018 Currently Reads:
Key Dates
Applications Due Date
New
Not applicable
RFA-DA-26-018 Modified to Read (in bold):
Key Dates
Applications Due Date
New
February 19, 2025
RFA-DA-26-018 and RFA-DA-26-019 Currently Reads:
Part 2. Full Text of Announcement
Section II. Award Information
Award Budget
Budgets up to $306,872 total costs for Phase I and up to $2,045,816 total costs for Phase II may be requested
RFA-DA-26-018 and RFA-DA-26-019 Modified to Read (in bold):
Part 2. Full Text of Announcement
Section II. Award Information
Award Budget
Budgets up to $314,363 total costs for Phase I and up to $2,095,748 total costs for Phase II may be requested
All other aspects of this NOFO remain unchanged.
Please direct all inquiries to:
Yordan Kostov, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-5650
Email: yordan.kostov@nih.gov